NanoKnife is a system used to deliver irreversible electroporation (IRE), an approach to treating selected areas of prostate cancer. Short electrical pulses disrupt the membranes of targeted cells, causing cell death. When used as focal therapy, treatment aims to address the cancerous area while limiting the amount of surrounding prostate tissue treated.
Who May Be Suitable for NanoKnife?
NanoKnife may be considered for carefully selected patients with biopsy-confirmed cancer that is confined to the prostate. Suitability depends on the cancer’s grade, location and extent, as well as your general health and test results.
A specialist review is essential. Active surveillance, prostate removal surgery and radiotherapy may also be appropriate options. The choice should reflect your cancer risk, priorities and the evidence supporting each approach.
How Is the Procedure Performed?
IRE is usually performed under general anaesthesia. Using imaging guidance, the specialist places thin needle electrodes through the perineum, the skin between the scrotum and anus, and into the prostate. Electrical pulses pass between the electrodes to treat the planned area.
A temporary urinary catheter is commonly needed while swelling settles. Discharge timing and recovery depend on your procedure and medical needs.
Potential Benefits and Limitations
Focal treatment aims to limit effects on nearby structures involved in urinary control and erections. Preservation of these functions cannot be guaranteed. IRE remains an evolving treatment, and evidence about long-term cancer control is less established than for surgery or radiotherapy.
Some international guidelines recommend offering IRE only within clinical trials. Your specialist should explain the evidence, the arrangements under which treatment is offered and how its uncertainties affect your decision.
Recovery, Risks and Follow-Up
Possible effects include discomfort, blood in the urine, urinary urgency, infection, difficulty passing urine, erection changes or urinary leakage. Rare serious complications can include injury to nearby structures.
Follow-up is essential because prostate tissue remains after focal treatment. Ongoing assessment generally includes PSA blood tests, MRI and repeat biopsy as advised. Cancer may persist or return, and further treatment may be needed.
